# Antihypertensive Medications and the Risk of Sepsis

> **NCT02248896** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1129062 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Telmisartan
- **DRUG:** Other angiotensin-receptor blockers (ARBs)
- **DRUG:** Angiotensin-converting enzyme inhibitors (ACEIs)
- **DRUG:** Other major antihypertensive medication classes

## Key facts

- **NCT ID:** NCT02248896
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2011-03
- **Final completion:** —
- **Target enrollment:** 1129062 (ACTUAL)
- **Last updated:** 2014-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02248896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02248896, "Antihypertensive Medications and the Risk of Sepsis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02248896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*